On August 9, 2023 Multifunctional IgG/IgM antibodies and cellular cytotoxicity are elicited by the full-length MSP1 SumayaVac-1 malaria vaccine candidate
On July 15, 2023 The malaria blood stage antigen PfCyRPA formulated with the TLR-4 agonist adjuvant GLA-SE elicits parasite growth inhibitory antibodies in experimental animals
On October 27, 2022 A novel asexual blood-stage malaria vaccine candidate: PfRipr5 formulated with human-use adjuvants induces potent growth inhibitory antibodies
On April 14, 2021 Accelerated phase 1a/b evaluation of the malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of humoral immune responses
On February 4, 2020 PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomized, double-blind, placebo-controlled study
On January 31, 2020 Immunization with full-length Plasmodium falciparum merozoite surface proetin 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial
